Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies

被引：30

作者：

Cummings, JL

Zhong, K

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA

[2] MediChamp, Newton, MA 02462 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 01期

关键词：

D O I：

10.1038/nrd1928

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Neuropsychiatric symptoms and behavioural alterations are common in neurodegenerative diseases, and effective treatment of these changes represents an important unmet public health need. Imaging, neuropathological, neurotransmitter and molecular genetic studies increasingly identify specific mechanisms that mediate behavioural changes in neurodegenerative disorders and provide a platform for seeking effective therapeutic interventions. Measuring behavioural outcomes in clinical trials of antidementia agents represents an important means of evaluating treatment effectiveness, and clinical trial methodologies and behavioural instrumentation are evolving to facilitate drug development in this important therapeutic target area.

引用

收藏

页码：64 / 74

页数：11

相关论文

共 129 条

[1]

Aarsland D, 2001, INT J GERIATR PSYCH, V16, P184, DOI 10.1002/1099-1166(200102)16:2<184::AID-GPS304>3.0.CO

[2]

2-K

[3] CORNELL SCALE FOR DEPRESSION IN DEMENTIA [J].

ALEXOPOULOS, GS ;

ABRAMS, RC ;

YOUNG, RC ;

SHAMOIAN, CA .

BIOLOGICAL PSYCHIATRY, 1988, 23 (03) :271-284

[4] Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease [J].

Assal, F ;

Alarcón, M ;

Solomon, EC ;

Masterman, D ;

Geschwind, DH ;

Cummings, JL .

ARCHIVES OF NEUROLOGY, 2004, 61 (08) :1249-1253

[5] Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial [J].

Ballard, C ;

Margallo-Lana, M ;

Juszczak, E ;

Douglas, S ;

Swann, A ;

Thomas, A ;

O'Brien, J ;

Everratt, A ;

Sadler, S ;

Maddison, C ;

Lee, L ;

Bannister, C ;

Elvish, R ;

Jacoby, R .

BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7496) :874-877

[6] The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: Persistence and new cases over 1 year of follow-up [J].

Ballard, CG ;

O'Brien, JT ;

Swann, AG ;

Thompson, P ;

Neill, D ;

McKeith, IG .

JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (01) :46-49

[7] Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies [J].

Ballard, CG ;

Jacoby, R ;

Del Ser, T ;

Khan, MN ;

Munoz, DG ;

Holmes, C ;

Nagy, Z ;

Perry, EK ;

Joachim, C ;

Jaros, E ;

O'Brien, JT ;

Perry, RH ;

McKeith, IG .

AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (05) :843-849

[8] Executive dysfunction and apathy predict functional impairment in Alzheimer disease [J].

Boyle, PA ;

Malloy, PF ;

Salloway, S ;

Cahn-Weiner, DA ;

Cohen, R ;

Cummings, JL .

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 11 (02) :214-221

[9] A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia [J].

Brodaty, H ;

Ames, D ;

Snowdon, J ;

Woodward, M ;

Kirwan, J ;

Clarnette, R ;

Lee, E ;

Lyons, B ;

Grossman, F .

JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (02) :134-143

[10]

Caligiuri MP, 1998, AM J GERIAT PSYCHIAT, V6, P75

← 1 2 3 4 5 6 7 8 9 10 →